AstraZeneca (AZN) stock declined 2% after positive Tezspire trial results. Pipeline setbacks weigh on shares despite analyst price targets showing 33% upside. The post AstraZeneca (AZN) Stock Slides Despite Positive Tezspire Trial Results appeared first on Blockonomi.